# US 2006/0189597 A1 · Lactam compounds and pharmaceutical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0189597 A1
- Document ID: US20060189597A1
- Status: Published application
- Kind: A1
- Application number: 11/398,675
- Filed: 2006-04-06
- Published: 2006-08-24
- Earliest claimed: 2000-12-01
- Assignees: Ajinomoto Co., Inc.
- Inventors: Yukio Ilno; Takao Ikenoue; Nobuo Kondo; Hiroyuki Matsueda; Toshihiro Hatanaka; Ryusuke Hirama; Yoko Masuzawa; Fumio Ohta; Akiyo Yamazaki; Seiji Niwa; Takashi Yamamoto
- Web page: https://patentgrep.com/patent/US20060189597A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 25/02: for peripheral neuropathies
- A61P 27/02: Ophthalmic agents
- C07D 243/10: condensed with carbocyclic rings or ring systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.

## Claims

### Claim at position 1

1: A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein A represents an aromatic ring, a heterocyclic ring or an aliphatic ring; R2, R3 and R4 may be the same or different from one another and independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a mercapto group, an alkoxyl group, an alkylthio group, an alkylsulfonyl group, an acyl group, an acyloxyl group, an amino group, an alkylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a nitro group, a cyano group, a trifluoromethyl group, an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), an aryl group which may have a substituent(s), a heteroaryl group which may have a substituent(s), a benzyloxyl group which may have a substituent(s), an aryloxyl group which may have a substituent(s), a heteroaryloxyl group which may have a substituent(s), an arylamino group which may have a substituent(s), an arylvinyl group which may have a substituent(s) or an arylethynyl group which may have a substituent(s); B represents a fused aliphatic ring which may have a substituent(s); —X— and —Y— may be the same or different from one another and they independently represent —NH— and —NR5—, wherein R5 represents a lower alkyl group which may have a substituent(s), an acyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s) or a sulfonyl group which may have a substituent(s); -Z- represents —CH2— or —CR6R7—, wherein R6 and R7 may be the same or different from each other and they independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group which may have a substituent(s), an aryl group, a mercapto group, an alkoxyl group, an alkylthio group, an alkylsulfonyl group, an acyl group, an acyloxyl group, an amino group, an alkylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a nitro group, a cyano group or a trifluoromethyl group; —W— represents —NR1—, wherein R1 represents a hydrogen atom, a lower alkyl group which may have a substituent(s) or an aryl group which may have a substituent(s); and a, b and c each represent the position of carbon atom;
said heterocyclic ring is selected from the group consisting of pyridine ring, dihydropyran ring, pyridazine ring, pyrimidine ring, pyrazine ring, pyrrole ring, furan ring, thiophene ring, oxazole ring, isoxazole ring, pyrazole ring, imidazole ring, thiazole ring, isothiazole ring, thiadiazole ring, pyrrolidine ring, piperidine ring, piperazine ring, indole ring, isoindole ring, benzofuran ring, isobenzofuran ring, benzothiophene ring, benzopyrazole ring, benzoimidazole ring, benzoxazole ring, benzothiazole ring, purine ring, pyrazolopyridine ring, quinoline ring, isoquinoline ring, naphthyridine ring, quinazoline ring, benzodiazepine ring, carbazole ring, and dibenzofuran ring;
said acyl group is selected from the group consisting of formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group, acryloyl group, methacryloyl group, crotonoyl group, isocrotonoyl group, benzoyl group, naphthoyl group, furanyl carbonyl group, thienyl carbonyl group, isoxazolyl carbonyl group, and thiazolyl carbonyl group;
said acyloxyl group is selected from the group consisting of formyloxyl group, acetyloxy group, propionyloxyl group, butyryloxyl group, isobutyryloxyl group, valeryloxyl group, isovaleryloxyl group, pivaloyloxyl group, hexanoyloxyl group, acryloyloxyl group, methacryloyloxyl group, crotonoyloxyl group, isocrotonoyloxyl group, benzoyloxyl group, and naphthoyloxyl group;
said heteroaryl group is selected from the group consisting of pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, pyrrolyl group, furanyl group, thienyl group, oxazolyl group, isoxazolyl group, pyrazolyl group, imidazolyl group, thiazolyl group, isothiazolyl group, thiadiazolyl group, indolyl group, isoindolyl group, benzofuryl group, isobenzofuryl group, benzothienyl group, benzopyrazolyl group, benzoimidazolyl group, benzoxazolyl group, benzothiazolyl group, quinolyl group, isoquinolyl group, naphthylidinyl group, quinazolyl group, oxadiazolyl group, and pyridonyl group;
said fused aliphatic ring is selected from the group consisting of cyclopropane ring, cyclobutane ring, cyclopentane ring, cyclohexane ring, cycloheptane ring, cyclooctane ring, and decalin ring, and wherein the substituent(s) is selected from the group consisting of halogen atoms, hydroxyl group, alkyl groups, mercapto group, alkoxyl groups, alkylthio groups, alkylsulfonyl groups, acyl groups, acyloxyl groups, amino group, alkylamino groups, carboxyl group, alkoxycarbonyl groups, carbamoyl groups, nitro group, cyano group, trifluoromethyl group, aryl groups and heteroaryl groups.

### Claim at position 2 (depends on 1)

2: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 3 (depends on 1)

3: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.

### Claim at position 4 (depends on 1)

4: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.

### Claim at position 5 (depends on 1)

5: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in general formula (I), R2, R3 and R4 may be the same or different from one another and independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a mercapto group, an alkoxyl group, an alkylthio group, an alkylsulfonyl group, an acyl group, an acyloxyl group, an amino group, an alkylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a nitro group, a cyano group, a trifluoromethyl group, an aryl group which may have a substituent(s), a heteroaryl group which may have a substituent(s), a benzyloxyl group which may have a substituent(s), an aryloxyl group which may have a substituent(s), a heteroaryloxyl group which may have a substituent(s), an arylamino group which may have a substituent(s), an arylvinyl group which may have a substituent(s) or an arylethynyl group which may have a substituent(s); —X— and —Y— may be the same or different from one another and they independently represent —NH— or —NR5—, wherein R5 represents a lower alkyl group or an acyl group which may have a substituent(s); -Z- represents —CH2— or —CR6R7—, wherein R6 and R7 may be the same or different from each other and they independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, an aryl group, a mercapto group, an alkoxyl group, an alkylthio group, an alkylsulfonyl group, an acyl group, an acyloxyl group, an amino group, an alkylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a nitro group, a cyano group or a trifluoromethyl group; and wherein:
(i) the substituent(s) is selected from the group consisting of halogen atoms, hydroxyl group, alkyl groups, aryl groups, mercapto group, alkoxyl groups, alkylthio groups, alkylsulfonyl groups, acyl groups, acyloxyl groups, amino group, alkylamino groups, carboxyl group, alkoxycarbonyl groups, carbamoyl groups, nitro group, cyano group and trifluoromethyl group.

### Claim at position 6 (depends on 5)

6: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 5 and a pharmaceutically acceptable carrier.

### Claim at position 7 (depends on 5)

7: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 5.

### Claim at position 8 (depends on 5)

8: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 5.

### Claim at position 9 (depends on 1)

9: The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein in general formula (I), -Z- represents —CH2— or —CR6R7— wherein R6 and R7 may be the same or different from each other and they independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a mercapto group, an alkoxyl group, an alkylthio group, an alkylsulfonyl group, an acyl group, an acyloxyl group, an amino group, an alkylamino group, a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, a nitro group, a cyano group or a trifluoromethyl group.

### Claim at position 10 (depends on 9)

10: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 9 and a pharmaceutically acceptable carrier.

### Claim at position 11 (depends on 9)

11: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 9.

### Claim at position 12 (depends on 9)

12: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 9.

### Claim at position 13 (depends on 9)

13: The compound or pharmaceutically acceptable salt thereof according to claim 9, wherein —Y— is —NR5—, wherein R5 represents an acyl group having 1 to 7 carbon atoms which may have a substituent selected from the group consisting of halogen atoms, lower alkyloxy groups, hydroxy group, furyl group, thienyl group, oxazolyl group, isoxazolyl group, thiazolyl group, pyridyl group, pyrimidyl group and imidazolyl group.

### Claim at position 14 (depends on 13)

14: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 13 and a pharmaceutically acceptable carrier.

### Claim at position 15 (depends on 13)

15: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 13.

### Claim at position 16 (depends on 13)

16: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 13.

### Claim at position 17 (depends on 9)

17: The compound or pharmaceutically acceptable salt thereof according to claim 9, wherein in general formula (I), B represents a cyclohexane ring which may have a substituent(s).

### Claim at position 18 (depends on 17)

18: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 17 and a pharmaceutically acceptable carrier.

### Claim at position 19 (depends on 17)

19: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 17.

### Claim at position 20 (depends on 17)

20: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 17.

### Claim at position 21 (depends on 17)

21: The compound or pharmaceutically acceptable salt thereof according to claim 17, wherein in general formula (I), A represents a benzene ring.

### Claim at position 22 (depends on 21)

22: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 21 and a pharmaceutically acceptable carrier.

### Claim at position 23 (depends on 21)

23: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 21.

### Claim at position 24 (depends on 21)

24: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 21.

### Claim at position 25 (depends on 21)

25: The compound or pharmaceutically acceptable salt thereof according to claim 21, wherein the absolute configuration of carbon atoms at a, b and c in general formula (I) is R or S independently from each other.

### Claim at position 26 (depends on 25)

26: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 25 and a pharmaceutically acceptable carrier.

### Claim at position 27 (depends on 25)

27: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 25.

### Claim at position 28 (depends on 25)

28: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 25.

### Claim at position 29 (depends on 25)

29: The compound or pharmaceutically acceptable salt thereof according to claim 25, wherein the absolute configuration of carbon atoms at both a and b in general formula (I) is R and the absolute configuration of carbon atom at c is R or S.

### Claim at position 30 (depends on 29)

30: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 29 and a pharmaceutically acceptable carrier.

### Claim at position 31 (depends on 29)

31: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 29.

### Claim at position 32 (depends on 29)

32: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 29.

### Claim at position 33 (depends on 25)

33: The compound or pharmaceutically acceptable salt thereof according to claim 25, wherein the absolute configuration of carbon atoms at both a and b in general formula (I) is S and the absolute configuration of carbon atoms in c is R or S.

### Claim at position 34 (depends on 33)

34: A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 33 and a pharmaceutically acceptable carrier.

### Claim at position 35 (depends on 33)

35: A method for treating hypoglycemia, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 33.

### Claim at position 36 (depends on 33)

36: A method for treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which comprises administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 33.
